Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Metrics to compare | NERV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNERVPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.9x | −3.1x | −0.6x | |
PEG Ratio | −0.05 | −0.02 | 0.00 | |
Price/Book | −0.7x | 3.0x | 2.6x | |
Price / LTM Sales | - | 61.9x | 3.3x | |
Upside (Analyst Target) | 115.5% | 232.9% | 45.3% | |
Fair Value Upside | Unlock | −1.5% | 6.1% | Unlock |